In susceptible mouse strains treatment with exogenous recombinant murine IL-12 reduced tuberculosis mortality [51], delayed mammary tumor onset with reduced tumor burden [52], and inhibited hepatitis B virus infection [53], apparently through the actions of IFN-γ. This evidence concerns the gene IFNG and hepatitis B virus infection.